The present invention relates to a method for prevention or treatment of metabolic disease, administering a composition containing bone morphogenetic protein 10 (BMP10) as an active ingredient, in which brown fat differentiation was promoted in the cells of BMP10-treated mouse embryonic mesenchymal cell line C3H10T1/T2, increased browning effects of stromal vascular fraction adipose stem cells isolated from subcutaneous adipose tissue was confirmed, and weight loss, improved insulin resistance, and changes in blood lipid levels were confirmed in a high-fat-diet-induced obese animal model. Therefore, the composition containing BMP10 as an active ingredient can be provided as a drug for the prevention or treatment of metabolic diseases, including obesity, diabetes, and dyslipidemia.

The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.

A method of promoting bone health in a moderately malnourished individual is provided. The method includes treating the moderately malnourished individual with a nutritional composition that contains a carbohydrate blend. The carbohydrate blend includes a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch.

The present disclosure provides a method to promote fat/weight loss of a subject, including the step of administering to the subject an effective amount of a composition comprising a lactate salt. The present disclosure also provides a method to prevent fat/weight gain of a subject while maintaining muscle mass.

The present invention is directed to functional food compositions comprising collagen. In one embodiment, the invention relates to a collagen and nut protein blend, wherein the composition is a solid or semi-solid that is shelf-stable and has a soft texture. The present invention also includes compositions with other nut protein blends, and compositions that further do not contain gluten. A method of making the compositions of the present invention is also claimed.

The present invention provides methods for enhancing and improving athletic performances of both professional and non-professional athletes by administering compositions comprising stabilized amorphous calcium carbonate. The enhanced athletic performances result among others from enhanced muscle performances, enhanced recovery and endurance.

A method is disclosed for making palatable methionine-restricted foods, to deliver a methionine-restricted diet to human or veterinary patients. A protein or a food product containing protein is partially oxidized, preferably with ozone, to oxidize nearly all of the methionine and cysteine. After oxidation, tryptophan and lysine are optionally added back since they tend to be oxidized also. Optionally, a small amount of methionine is also added back so that the final methionine is within a preferred range of about 0.85 to about 1.8 gram methionine per 100 gram total protein, preferably about 1.2 gram per 100 gram total protein.

The present disclosure encompasses compositions prepared from Boysenberry and apple, as well as compositions prepared from Boysenberry, apple and blackcurrant. Also encompassed are methods of preparing these compositions and methods of using these compositions, in particular, for treating or preventing disorders of the respiratory system, including amongst others: inflammation, asthma, chronic obstructive pulmonary disease, allergic airways inflammation, reactive airway disease, airway fibrosis, and airway remodelling.

An oxidative stress inhibitor 100 of the present invention contains silicon particles capable of generating hydrogen. In a preferred aspect of the oxidative stress inhibitor 100, the following effects (a) and/or (b) can be exhibited. (a) The total amount of generation (total amount of production) is increased. (b) The amount of generation of hydrogen per unit time (i.e. rate of generation of hydrogen), particularly the rate of generation of hydrogen in the initial stage is increased.

Provided are nutritional compositions having a protein component that includes certain peptides and/or bioactive peptides. Further disclosed are nutritional composition having a protein source that includes intact protein, beta-casein enriched casein hydrolysate, and/or peptides weighing from about 500 Da to about 1,999 Da. The nutritional compositions disclosed are suitable for administration to pediatric subjects, such as infants.